LitAlert ~~

    • Population Study of Ovarian Cancer Risk Prediction for Targeted Screening and Prevention.
    • Gaba F, Blyuss O, Liu X, Goyal S, Lahoti N, Chandrasekaran D, Kurzer M, Kalsi J, Sanderson S, Lanceley A, Ahmed M, Side L, Gentry-Maharaj A, Wallis Y, Wallace A, Waller J, Luccarini C, Yang X, Dennis J, Dunning A, Lee A, Antoniou AC, Legood R, Menon U, Jacobs I, Manchanda R.
    • Cancers (Basel). 2020 May 15;12(5):E1241. doi: 10.3390/cancers12051241.
    • Cisplatin Plus Gemcitabine as Standard of Care for Germline BRCA/PALB2-Mutated Pancreatic Adenocarcinoma: Are We Moving Too Fast?
    • Fazio N.
    • J Clin Oncol. 2020 May 14:JCO2000419. doi: 10.1200/JCO.20.00419. Epub ahead of print.

    Original research:

    Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation.

    • [Molecular predictors for the course of disease and individualized therapy in pancreatic cancer].
    • Damanakis AI, Gebauer F, Bruns CJ. Molekulare Prädiktoren für den Krankheitsverlauf und die individualisierte Therapie beim Pankreaskarzinom
    • Chirurg. 2020 May 13. German. doi: 10.1007/s00104-020-01172-0. Epub ahead of print.
    • Review, [Article in German]